BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han R, Zhou J, François C, Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. BMC Infect Dis 2019;19:655. [PMID: 31337339 DOI: 10.1186/s12879-019-4284-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Kwan TH, Wong BCK, Wong KH, Lee SS. Hepatitis C Co-infection in People Living With HIV—Epidemiologic Differences Between Men Who Have Sex With Men MSM and Non-MSM. Front Public Health 2022;10:925600. [DOI: 10.3389/fpubh.2022.925600] [Reference Citation Analysis]
2 Folch C, Saludes V, Reyes-Ureña J, Antuori A, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants. Int J Drug Policy 2021;90:103057. [PMID: 33310634 DOI: 10.1016/j.drugpo.2020.103057] [Reference Citation Analysis]
3 Rashti R, Sharafi H, Alavian SM, Moradi Y, Mohamadi Bolbanabad A, Moradi G. Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. Pathogens 2020;9:E432. [PMID: 32486342 DOI: 10.3390/pathogens9060432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Carty PG, Fawsitt CG, Gillespie P, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations. Appl Health Econ Health Policy 2021. [PMID: 34870793 DOI: 10.1007/s40258-021-00694-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Uusküla A, Talu A, Rannap J, Barnes DM, Jarlais DD. Rapid point-of-care (POC) testing for Hepatitis C antibodies in a very high prevalence setting: persons injecting drugs in Tallinn, Estonia. Harm Reduct J 2021;18:39. [PMID: 33794927 DOI: 10.1186/s12954-021-00485-5] [Reference Citation Analysis]
6 Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. BMC Public Health 2020;20:1670. [PMID: 33167912 DOI: 10.1186/s12889-020-09515-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shabani M, Sadegh Ehdaei B, Fathi F, Dowran R. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect 2021;42:100895. [PMID: 33976895 DOI: 10.1016/j.nmni.2021.100895] [Reference Citation Analysis]
8 Safdari R, Deghatipour A, Gholamzadeh M, Maghooli K. Applying data mining techniques to classify patients with suspected hepatitis C virus infection. Intelligent Medicine 2022. [DOI: 10.1016/j.imed.2021.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kamali I, Barnhart DA, Nyirahabihirwe F, de la Paix Gakuru J, Uwase M, Nizeyumuremyi E, Walker S, Mazimpaka C, de Dieu Gatete J, Makuza JD, Serumondo J, Kateera F, d'Amour Ndahimana J. Initiation of hepatitis C treatment in two rural Rwandan districts: a mobile clinic approach. BMC Infect Dis 2021;21:220. [PMID: 33632165 DOI: 10.1186/s12879-021-05920-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pena DZ, Anadão MF, Flores EF, Okada MN, Filho AMP, Ferro RS, Prestes-Carneiro LE. Clinical, Epidemiological, and Geospatial Characteristics of Patients Infected with Hepatitis C Virus Treated with Second-Generation Direct-Action Antivirals in a Reference Center in a Mesoregion of São Paulo State, Brazil. Microorganisms 2020;8:E1575. [PMID: 33066136 DOI: 10.3390/microorganisms8101575] [Reference Citation Analysis]
11 Prabdial-Sing N, Gaelejwe L, Makhathini L, Thaver J, Manamela MJ, Malfeld S, Spearman CW, Sonderup M, Scheibe A, Young K, Hausler H, Puren AJ. The performance of hepatitis C virus (HCV) antibody point-of-care tests on oral fluid or whole blood and dried blood spot testing for HCV serology and viral load among individuals at higher risk for HCV in South Africa. Health Sci Rep 2021;4:e229. [PMID: 33614978 DOI: 10.1002/hsr2.229] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res 2020;48:300060520964659. [PMID: 33111612 DOI: 10.1177/0300060520964659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mangia A, Cenderello G, Verucchi G, Ciancio A, Fontana A, Piazzolla V, Minerva N, Squillante MM, Copetti M. Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis? World J Clin Cases 2020; 8(22): 5831-5834 [PMID: 33344581 DOI: 10.12998/wjcc.v8.i22.5831] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Kozlowski HN, Sindhwani S, Chan WCW. The Impact of Patient Characteristics on Diagnostic Test Performance. Small Methods 2022;:e2101233. [PMID: 34994108 DOI: 10.1002/smtd.202101233] [Reference Citation Analysis]
15 Reyes-Urueña J, Celly A, Moreno S, Majó X, Colom J, Casabona J. Hepatitis C virus: Testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016. J Viral Hepat 2021;28:288-99. [PMID: 33098176 DOI: 10.1111/jvh.13427] [Reference Citation Analysis]
16 Lanièce Delaunay C, Cox J, Klein M, Lambert G, Grace D, Lachowsky NJ, Maheu-Giroux M. Trends in hepatitis C virus seroprevalence and associated risk factors among men who have sex with men in Montréal: results from three cross-sectional studies (2005, 2009, 2018). Sex Transm Infect 2021;97:290-6. [PMID: 32703845 DOI: 10.1136/sextrans-2020-054464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Han R, François C, Toumi M. Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results. Appl Health Econ Health Policy 2021;19:29-44. [PMID: 32661846 DOI: 10.1007/s40258-020-00600-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Timofte D, Dragos D, Balcangiu-Stroescu AE, Tanasescu MD, Gabriela Balan D, Avino A, Tulin A, Stiru O, Ionescu D. Infection with hepatitis C virus in hemodialysis patients: An overview of the diagnosis and prevention rules within a hemodialysis center (Review). Exp Ther Med 2020;20:109-16. [PMID: 32509002 DOI: 10.3892/etm.2020.8606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Carty PG, McCarthy M, O'Neill SM, De Gascun CF, Harrington P, O'Neill M, Smith SM, Teljeur C, Ryan M. Laboratory-based testing for hepatitis C infection using dried blood spot samples: A systematic review and meta-analysis of diagnostic accuracy. Rev Med Virol 2021;:e2320. [PMID: 34957630 DOI: 10.1002/rmv.2320] [Reference Citation Analysis]
20 Fabbiani M, Lombardi A, Colaneri M, Del Poggio P, Perini P, D'Ambrosio R, Degasperi E, Dibenedetto C, Giorgini A, Pasulo L, Maggiolo F, Castelli F, Brambilla P, Spinelli O, Re T, Lleo A, Rumi M, Uberti-Foppa C, Soria A, Aghemo A, Lampertico P, Baiguera C, Schiavini M, Fagiuoli S, Bruno R; NAVIGATORE-Lombardia Study Group. High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. J Viral Hepat 2021;28:558-68. [PMID: 33306247 DOI: 10.1111/jvh.13454] [Reference Citation Analysis]
21 Hamadeh A, Haines A, Feng Z, Thein HH, Janjua NZ, Krahn M, Wong WWL. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat 2020;27:1419-29. [PMID: 32810886 DOI: 10.1111/jvh.13373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Han R, Liang S, François C, Aballea S, Clay E, Toumi M. Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. J Mark Access Health Policy 2021;9:1887664. [PMID: 33828822 DOI: 10.1080/20016689.2021.1887664] [Reference Citation Analysis]
23 Matičič M, Lombardi A, Mondelli MU, Colombo M; ESCMID Study Group for Viral Hepatitis (ESGVH). Elimination of hepatitis C in Europe: can WHO targets be achieved? Clin Microbiol Infect 2020;26:818-23. [PMID: 31978546 DOI: 10.1016/j.cmi.2020.01.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
24 Aas CF, Vold JH, Skurtveit S, Odsbu I, Chalabianloo F, Lim AG, Johansson KA, Fadnes LT. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Subst Abuse Treat Prev Policy 2020;15:44. [PMID: 32605625 DOI: 10.1186/s13011-020-00286-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Villani R, Cavallone F, Romano AD, Bellanti F, Serviddio G. Two-Dimensional Shear Wave Elastography versus Transient Elastography: A Non-Invasive Comparison for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C. Diagnostics (Basel) 2020;10:E313. [PMID: 32429410 DOI: 10.3390/diagnostics10050313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Meester I, Manilla-Muñoz E, León-Cachón RBR, Paniagua-Frausto GA, Carrión-Alvarez D, Ruiz-Rodríguez CO, Rodríguez-Rangel X, García-Martínez JM. SeXY chromosomes and the immune system: reflections after a comparative study. Biol Sex Differ 2020;11:3. [PMID: 31937374 DOI: 10.1186/s13293-019-0278-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
27 Busschots D, Bielen R, Koc ÖM, Heyens L, Verrando R, de Galocsy C, Van Steenkiste C, Nevens F, Midgard H, Dalgard O, Robaeys G. Hepatitis C reinfection in former and active injecting drug users in Belgium. Harm Reduct J 2021;18:102. [PMID: 34641896 DOI: 10.1186/s12954-021-00552-x] [Reference Citation Analysis]
28 Ohlendorf V, Schäfer A, Christensen S, Heyne R, Naumann U, Link R, Herold C, Schiffelholz W, Günther R, Cornberg M, Serfert Y, Maasoumy B, Wedemeyer H, Kraus MR. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). J Viral Hepat 2021;28:1206-18. [PMID: 34003549 DOI: 10.1111/jvh.13546] [Cited by in F6Publishing: 1] [Reference Citation Analysis]